Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

Amarin Corp. ADR Stock

Price
Target price
-

-

-
-
-
-
 
WKN: A0NBNG / Symbol: AMRN / Name: Amarin / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Amarin Corp. ADR in the next few years
Wizard

Amarin Corp. ADR Stock

Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Amarin Corp. ADR stock. Negative votes have not been in the majority for any criteria for this stock

Amarin Corporation plc (Symbol AMRN) is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to improve cardiovascular health. The company's main product, Vascepa, is a prescription medication that has been approved by the US FDA for use as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia. Vascepa has also shown to reduce the risk of cardiovascular events such as heart attack and stroke in patients with elevated cardiovascular risk. As a listed company, Amarin is publicly traded on the NASDAQ stock exchange and has a market capitalization of approximately $5 billion as of August 2021.

AI-generated

Pros and Cons of Amarin Corp. ADR in the next few years

Pros
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Amarin Corp. ADR vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Amarin Corp. ADR - - - - - - -
Genus plc -1.550% 2.419% 3.252% -10.563% -13.605% -10.500% -60.620%
United Therapeutics -0.720% -0.801% -3.900% 78.050% 7.255% 105.978% 195.677%
Ligand Pharmaceuticals -1.540% -5.970% -8.029% 115.385% 51.807% 309.756% 147.180%

Comments

Prediction Sell
Perf. (%) -
Target price 10.319
Change
Ends at 25.06.26

Amarin Corporation PLC (NASDAQ: AMRN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $7.00 to $12.00. They now have a "sell" rating on the stock.
Ratings data for AMRN provided by MarketBeat
Show more

The Goldman Sachs Group, Inc. 
0
Report Share
25.06.25
Prediction Sell
Perf. (%) -
Target price 6.160
Change
Ends at 17.04.26

Amarin Co. plc (NASDAQ: AMRN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $20.00 to $7.00. They now have a "sell" rating on the stock.
Ratings data for AMRN provided by MarketBeat
Show more

The Goldman Sachs Group, Inc. 
0
Report Share
17.04.25

Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for AMRN provided by MarketBeat
Show more

StockNews.com 
0
Report Share
23.03.25 Sell -2.75%
Show more
Not a member yet? Sign up for free!

News

Amarin Q2 Earnings Call HighlightsPhoto, wide shot, wide-angle lens, soft focus, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-pKgbwxVSbyTCu0UzPNe8NL8D.png?st=2023-05-04T16%3A02%3A58Z&se=2023-05-04T18%3A02%3A58Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T12%3A13%3A51Z&ske=2023-05-05T12%3A13%3A51Z&sks=b&skv=2021-08-06&sig=%2BhYssNp3W0HiZMxCV64XVELyP8stYUjFhgUVfPrTLyg%3D
Amarin Q2 Earnings Call Highlights

Key Points

MarketBeat 
0 29.07.26
Liquidia Q1 Earnings Call HighlightsPhoto, wide shot, wide-angle lens, soft focus, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-d5U47McddROtnUwv1JIaZvc2.png?st=2023-05-04T16%3A11%3A57Z&se=2023-05-04T18%3A11%3A57Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T16%3A04%3A37Z&ske=2023-05-05T16%3A04%3A37Z&sks=b&skv=2021-08-06&sig=KvGLXJQj4L2uYw31IYBsPpHX4telRq/7natMW2uEF58%3D
Liquidia Q1 Earnings Call Highlights

Liquidia (NASDAQ:LQDA) reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain

MarketBeat 
0 11.05.26
Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition RisksPhoto, wide shot, wide-angle lens, soft focus, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-d5U47McddROtnUwv1JIaZvc2.png?st=2023-05-04T16%3A11%3A57Z&se=2023-05-04T18%3A11%3A57Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T16%3A04%3A37Z&ske=2023-05-05T16%3A04%3A37Z&sks=b&skv=2021-08-06&sig=KvGLXJQj4L2uYw31IYBsPpHX4telRq/7natMW2uEF58%3D
Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks

Amarin (NASDAQ: AMRN) is a drug company that is in a particularly precarious position. This fact is highlighted by the company's recent move to restructure its operations in an effort to cut costs

TheMotleyFool 
0 07.03.26